Champions Oncology, Inc.
CSBR
$7.63
$0.222.97%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.94M | 58.59M | 53.57M | 51.66M | 50.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.94M | 58.59M | 53.57M | 51.66M | 50.16M |
| Cost of Revenue | 28.39M | 28.37M | 29.60M | 28.79M | 29.40M |
| Gross Profit | 28.56M | 30.22M | 23.97M | 22.87M | 20.75M |
| SG&A Expenses | 16.89M | 16.59M | 16.95M | 17.70M | 18.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.10M | 51.87M | 53.92M | 54.69M | 57.08M |
| Operating Income | 4.85M | 6.72M | -352.00K | -3.04M | -6.92M |
| Income Before Tax | 4.63M | 6.40M | -636.00K | -3.44M | -7.31M |
| Income Tax Expenses | -74.00K | -26.00K | -38.00K | -38.00K | -31.00K |
| Earnings from Continuing Operations | 4.70 | 6.43 | -0.60 | -3.40 | -7.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.70M | 6.43M | -598.00K | -3.40M | -7.28M |
| EBIT | 4.85M | 6.72M | -352.00K | -3.04M | -6.92M |
| EBITDA | 6.49M | 8.43M | 1.43M | -1.17M | -5.05M |
| EPS Basic | 0.34 | 0.47 | -0.04 | -0.25 | -0.54 |
| Normalized Basic EPS | 0.23 | 0.31 | -0.01 | -0.14 | -0.32 |
| EPS Diluted | 0.32 | 0.44 | -0.06 | -0.26 | -0.54 |
| Normalized Diluted EPS | 0.21 | 0.30 | -0.01 | -0.14 | -0.32 |
| Average Basic Shares Outstanding | 54.64M | 54.48M | 54.38M | 54.28M | 54.19M |
| Average Diluted Shares Outstanding | 56.18M | 56.02M | 55.25M | 54.73M | 54.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |